{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:14Z","timestamp":1793831294022,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific and Technologial Innovation Programs of Higher Education Institutions in Shanxi","award":["2022L210"],"award-info":[{"award-number":["2022L210"]}]},{"name":"Fundamental Research Program of Shanxi Province","award":["202403021221329"],"award-info":[{"award-number":["202403021221329"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04721-9","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:23:26Z","timestamp":1744176206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ACVRL1 variation-induced hereditary hemorrhagic telangiectasia presenting with pulmonary arterial hypertension: clinical and genetic analyses of three case studies"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhixin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nating","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxuan","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"4","key":"4721_CR1","doi-asserted-by":"publisher","first-page":"e176379","DOI":"10.1172\/JCI176379","volume":"134","author":"T Al Tabosh","year":"2024","unstructured":"Al Tabosh T, Al Tarrass M, Tourvieilhe L, Guilhem A, Dupuis-Girod S, Bailly S. Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances. J Clin Invest. 2024;134(4):e176379.","journal-title":"J Clin Invest"},{"issue":"3","key":"4721_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000458447","volume":"94","author":"V Vorselaars","year":"2017","unstructured":"Vorselaars V, Velthuis S, van Gent M, et al. Pulmonary hypertension in a large cohort with hereditary hemorrhagic telangiectasia. Respiration. 2017;94(3):242\u201350.","journal-title":"Respiration"},{"issue":"7","key":"4721_CR3","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.3390\/ijms22073471","volume":"22","author":"S Bofarid","year":"2021","unstructured":"Bofarid S, Hosman AE, Mager JJ, Snijder RJ, Post MC. Pulmonary vascular complications in hereditary hemorrhagic telangiectasia and the underlying pathophysiology. Int J Mol Sci. 2021;22(7):3471.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4721_CR4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.7326\/L21-0068","volume":"174","author":"MS Clancy","year":"2021","unstructured":"Clancy MS, Palmer S, Olitsky S, Crocioni C, Plahn B. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2021;174(7):1036.","journal-title":"Ann Intern Med"},{"issue":"6","key":"4721_CR5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.blre.2010.07.001","volume":"24","author":"CL Shovlin","year":"2010","unstructured":"Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24(6):203\u201319.","journal-title":"Blood Rev"},{"key":"4721_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2015.00001","volume":"6","author":"J McDonald","year":"2015","unstructured":"McDonald J, Wooderchak-Donahue W, VanSant Webb C, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015;6:1.","journal-title":"Front Genet"},{"issue":"7","key":"4721_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1161\/01.RES.0000095246.40391.3B","volume":"93","author":"T Seki","year":"2003","unstructured":"Seki T, Yun J, Oh SP. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res. 2003;93(7):682\u20139.","journal-title":"Circ Res"},{"issue":"8","key":"4721_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1164\/rccm.200908-1284OC","volume":"181","author":"B Girerd","year":"2010","unstructured":"Girerd B, Montani D, Coulet F, et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med. 2010;181(8):851\u201361.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4721_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJM200108023450503","volume":"345","author":"RC Trembath","year":"2001","unstructured":"Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001;345(5):325\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"4721_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1253\/circj.72.127","volume":"72","author":"M Fujiwara","year":"2008","unstructured":"Fujiwara M, Yagi H, Matsuoka R, et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J. 2008;72(1):127\u201333.","journal-title":"Circ J"},{"key":"4721_CR11","doi-asserted-by":"crossref","unstructured":"Harrison RE, Flanagan JA, Sankelo M et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia [published correction appears in J Med Genet. 2004;41(7):576]. J Med Genet. 2003;40(12):865\u2013871.","DOI":"10.1136\/jmg.40.12.865"},{"issue":"1","key":"4721_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/jcm13010141","volume":"13","author":"P Jamindar","year":"2023","unstructured":"Jamindar P, Pope M, Gossage J. Long term survival of heritable pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia: A case series. J Clin Med. 2023;13(1):141.","journal-title":"J Clin Med"},{"issue":"4","key":"4721_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1358863X18767761","volume":"23","author":"F Droege","year":"2018","unstructured":"Droege F, Thangavelu K, Stuck BA, Stang A, Lang S, Geisthoff U. Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia. Vasc Med. 2018;23(4):377\u201383.","journal-title":"Vasc Med"},{"issue":"2","key":"4721_CR14","doi-asserted-by":"publisher","first-page":"204589401875991","DOI":"10.1177\/2045894018759918","volume":"8","author":"W Li","year":"2018","unstructured":"Li W, Xiong CM, Gu Q, et al. The clinical characteristics and long-term prognosis of pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia. Pulm Circ. 2018;8(2):2045894018759918.","journal-title":"Pulm Circ"},{"issue":"4","key":"4721_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1253\/circj.CJ-17-0299","volume":"82","author":"T Nakamura","year":"2018","unstructured":"Nakamura T, Ogo T, Tahara N, et al. Thalidomide for hereditary hemorrhagic telangiectasia with pulmonary arterial hypertension. Circ J. 2018;82(4):1205\u20137.","journal-title":"Circ J"},{"key":"4721_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijcard.2016.03.211","volume":"214","author":"R Miyake","year":"2016","unstructured":"Miyake R, Fujino T, Abe K, et al. Pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia successfully treated with sildenafil. Int J Cardiol. 2016;214:275\u20136.","journal-title":"Int J Cardiol"},{"key":"4721_CR17","doi-asserted-by":"publisher","first-page":"102033","DOI":"10.1016\/j.pupt.2021.102033","volume":"68","author":"E Abston","year":"2021","unstructured":"Abston E, Hon S, Rodriguez-Lopez J, et al. Treatment of pulmonary hypertension in patients with hereditary hemorrhagic Telangiectasia - A case series and systematic review. Pulm Pharmacol Ther. 2021;68:102033.","journal-title":"Pulm Pharmacol Ther"},{"issue":"11","key":"4721_CR18","doi-asserted-by":"publisher","first-page":"e003896","DOI":"10.1161\/JAHA.116.003896","volume":"5","author":"A Wei","year":"2016","unstructured":"Wei A, Gu Z, Li J, et al. Clinical adverse effects of endothelin receptor antagonists: insights from the Meta-Analysis of 4894 patients from 24 randomized Double-Blind Placebo-Controlled clinical trials. J Am Heart Assoc. 2016;5(11):e003896. Published 2016 Oct 26.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"4721_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/2045893217719250","volume":"7","author":"M Kingman","year":"2017","unstructured":"Kingman M, Archer-Chicko C, Bartlett M, Beckmann J, Hohsfield R, Lombardi S. Management of Prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ. 2017;7(3):598\u2013608.","journal-title":"Pulm Circ"},{"issue":"1","key":"4721_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.110.944603","volume":"122","author":"BG Schwartz","year":"2010","unstructured":"Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation. 2010;122(1):88\u201395.","journal-title":"Circulation"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04721-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04721-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04721-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:23:29Z","timestamp":1744176209000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04721-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4721"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04721-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Shanxi Cardiovascular Hospital Affiliated Shanxi Medical University (No.2024wjw101).Written informed consent was obtained from all patients involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}